ArticleAmerican journal of hematology2025
Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy.
Abstract read
In one paragraph
Article in American journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myeloma.HemaSphere · 2026Article
- Challenges and Potential Solutions to Advance Global Cancer Drug Development.Therapeutic innovation & regulatory science · 2026Review
- Real-world evidence of measurable residual disease assessment in multiple myeloma.Blood advances · 2026Article
- Evidence for the Monitoring of Minimal Residual Disease Dynamics to Guide Clinical Practice in Patients with Multiple Myeloma.Targeted oncology · 2026Review
- The Evolving Landscape of Anti-Clonal Therapy in Newly Diagnosed Systemic Light-Chain (AL) Amyloidosis: Evidence- and Time-Based Comparison with Multiple Myeloma.Life (Basel, Switzerland) · 2026Review
- Clinical applications of mass spectrometry in multiple myeloma.Blood advances · 2025Review
- MRD in multiple myeloma: the clinical perspective.Frontiers in oncology · 2025Review
- Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy.American journal of hematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Aintzane ZabaletaCancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain.ORCID 0000-0003-3474-3040
Noemi PuigHospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca, Salamanca, Spain.
Maria-Teresa CedenaServicio de Hematología y Hemoterapia, Hospital 12 de Octubre, Madrid, Spain.ORCID 0000-0001-5851-3720
Aina Oliver-CaldesHospital Clinic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
José J PerezHospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca, Salamanca, Spain.
Cristina MorenoCancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
Luis-Esteban Tamariz-AmadorCancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain.ORCID 0000-0002-4088-0992
Paula Rodriguez-OteroCancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
Felipe ProsperCancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
Veronica Gonzalez-CalleHospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca, Salamanca, Spain.
Lucía López-CorralHospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca, Salamanca, Spain.ORCID 0000-0003-1908-5596
Beatriz Rey-BúaHospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca, Salamanca, Spain.
Borja PuertasHospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca, Salamanca, Spain.
Fátima MirásServicio de Hematología y Hemoterapia, Hospital 12 de Octubre, Madrid, Spain.
José María Sánchez-PinaServicio de Hematología y Hemoterapia, Hospital 12 de Octubre, Madrid, Spain.ORCID 0000-0002-9181-0900
Nieves López-MuñozServicio de Hematología y Hemoterapia, Hospital 12 de Octubre, Madrid, Spain.ORCID 0000-0003-0090-6673
Manel JuanHospital Clinic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.ORCID 0000-0002-3064-1648
E Azucena González-NavarroHospital Clinic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
Álvaro UrbanoHospital Clinic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
Carlos Fernández de LarreaHospital Clinic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
Joan BladeHospital Clinic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
Juan-José LahuertaHospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca, Salamanca, Spain.
Joaquín Martinez-LopezServicio de Hematología y Hemoterapia, Hospital 12 de Octubre, Madrid, Spain.ORCID 0000-0001-7908-0063
Maria-Victoria MateosHospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca, Salamanca, Spain.
Jesús F San MiguelCancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
Bruno PaivaCancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
Funding
Black Swan Research Initiative of the International Myeloma FoundationCancer Research UK (A26819), FCAECC and AIRC under the Accelerator Award Programme (EDITOR)CIBER-Consorcio Centro de Investigación Biomédica en Red - Área de Oncología - Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación CB16/12/00233CIBER-Consorcio Centro de Investigación Biomédica en Red - Área de Oncología - Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación CB16/12/00369CIBER-Consorcio Centro de Investigación Biomédica en Red - Área de Oncología - Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación CB16/12/00489CRIS Cancer Foundation PR_EX_2020-02Fundación Científica Asociación Española Contra el CáncerInstituto de Salud Carlos III/Subdirección General de Investigación Sanitaria, (cofunded by the EU) ICI19/00025Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria, (cofunded by the EU) PI19/01451Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria, (cofunded by the EU) PI21/01816Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria, (cofunded by the EU) PI22/00647La Caixa Foundation CP042702/LCF/PR/GN18/50310007Riney Family Multiple Myeloma Research Program
Abstract
The impact of measurable residual disease (MRD) in relapse/refractory multiple myeloma (RRMM) patients treated with T-cell redirecting immunotherapy is uncertain. We analyzed MRD dynamics using next-generation flow in 201 patients treated in clinical trials with chimeric antigen receptor (CAR) T cells and T-cell engagers (TCE). Achieving MRD negativity at 10
Indexed as
Immunotherapy, AdoptiveMultiple MyelomaNeoplasm, ResidualRemission InductionAdultAgedClinical RelevanceFemaleHumansMaleMiddle AgedReceptors, Chimeric AntigenRecurrenceT-LymphocytesReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.